{"filing":{"accession_number":"0001193125-26-324972","cik":"0002044725","ticker":"EVMN","company_name":"Evommune, Inc.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-29","primary_document":"evmn-20260731.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526324972/evmn-20260731.htm"},"events":[{"id":22114,"run_id":19983,"accession_number":"0001193125-26-324972","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Evommune announced initiation of a Phase 2b clinical trial for EVO756, a MRGPRX2 inhibitor in migraine prophylaxis, with top-line data expected in 2027. This is a material operational and clinical development milestone for a clinical-stage biotech company, representing significant progress in its pipeline. While not fitting a specific named event type, this clinical trial initiation is clearly an operational/strategic business event material to investors assessing the company's development progress and commercial prospects.","company_name":"Evommune, Inc.","ticker":"EVMN","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":21965,"accession_number":"0001193125-26-324972","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Evommune announced initiation of a Phase 2b clinical trial for EVO756, a MRGPRX2 inhibitor in migraine prophylaxis, with top-line data expected in 2027. This is a material operational and clinical development milestone for a clinical-stage biotech company, representing significant progress in its pipeline. While not fitting a specific named event type, this clinical trial initiation is clearly an operational/strategic business event material to investors assessing the company's development progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T12:02:08.851264+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21965,"accession_number":"0001193125-26-324972","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Evommune announced initiation of a Phase 2b clinical trial for EVO756, a MRGPRX2 inhibitor in migraine prophylaxis, with top-line data expected in 2027. This is a material operational and clinical development milestone for a clinical-stage biotech company, representing significant progress in its pipeline. While not fitting a specific named event type, this clinical trial initiation is clearly an operational/strategic business event material to investors assessing the company's development progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T12:02:08.851264+00:00","company_name":"Evommune, Inc.","ticker":"EVMN","filing_date":"2026-07-30"}]}